Watson Reaches Deal With J&J For Concerta Generic

Law360, New York (November 3, 2010, 4:05 PM EDT) -- Johnson & Johnson has inked a deal giving Watson Laboratories Inc. a window to distribute an authorized generic version of its blockbuster attention deficit hyperactivity disorder treatment Concerta while the company pursues regulatory approval of its own generic version.

Under the terms of the supply and distribution agreement with J&J unit Ortho-McNeil-Janssen Pharmaceuticals Inc. announced Tuesday, Watson will be able to launch the authorized generic beginning May 1, 2011. Concerta had sales of approximately $1.3 billion for the 12-month period ending June 30, 2010, Watson noted....
To view the full article, register now.